Payment overview · 2025
General Payments
$241,236.20
522 reported records · 30 companies
Healthcare provider profile · identity verified
Barry K Vaught, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · CRAB ORCHARD, WV · NPI 1194770339
Verified facts
What the public records show
CMS Open Payments records show Barry K Vaught, M.D. received $241,236.20 in general payments during 2025 across 522 reported records.
ARGENX US, INC. accounted for 29.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Briviact, Fycompa, Ingrezza, Nayzilam, Nuplazid, Nurtec Odt, Qulipta, Rexulti, Ubrelvy, Valtoco, Xcopri.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Ubrelvy by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Nuplazid by this doctor in 2024.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Fycompa by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Privigen as an associated drug or biological on 464 records involving 289 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Privigen by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
Neurelis, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VALTOCO as an associated drug or biological on 16082 records involving 5567 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Valtoco by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Ingrezza by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MAYZENT as an associated drug or biological on 26 records involving 26 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mayzent by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 293 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Xcopri by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trintellix by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Austedo by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Austedo Xr by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Briviact by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nayzilam as an associated drug or biological on 9542 records involving 3826 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Nayzilam by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $70,498.49 | 29.2% | 68 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $38,835.02 | 16.1% | 50 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $22,284.45 | 9.2% | 26 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $20,021.97 | 8.3% | 27 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $18,963.46 | 7.9% | 32 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $18,461.87 | 7.7% | 27 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $14,371.51 | 6.0% | 32 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13,422.50 | 5.6% | 63 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $9,290.20 | 3.9% | 24 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$7,863.44 | 3.3% | 25 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$4,834.53 | 2.0% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $451.63 | 0.2% | 40 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $310.43 | 0.1% | 11 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $233.48 | 0.1% | 12 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $232.74 | 0.1% | 12 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $201.17 | 0.1% | 10 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $163.03 | 0.1% | 8 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $135.26 | 0.1% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $126.68 | 0.1% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $104.30 | 0.0% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $75.19 | 0.0% | 4 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $57.38 | 0.0% | 3 | 2025 |
| Life Molecular Imaging Ltd | Unresolved — no canonical attribution shown | $54.54 | 0.0% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $53.60 | 0.0% | 2 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $48.28 | 0.0% | 3 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $33.91 | 0.0% | 2 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.28 | 0.0% | 2 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $32.13 | 0.0% | 1 | 2025 |
| Genentech, Inc. | Unresolved — no canonical attribution shown | $30.80 | 0.0% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $11.93 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $167,523.00 | 52 |
| Consulting Fee | $21,776.45 | 27 |
| Travel and Lodging | $16,321.15 | 73 |
| Compensation for serving as faculty or as a speaker for a medical education program | $15,230.00 | 8 |
| Honoraria | $10,300.00 | 3 |
| Food and Beverage | $9,964.40 | 356 |
| Education | $121.20 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VYVGART Normalized: vyvgart |
Biological, Drug | ARGENX US, INC. | $68,309.92 | 60 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $38,835.02 | 50 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $22,185.45 | 25 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $18,461.87 | 27 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $15,237.46 | 28 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $14,371.51 | 32 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13,229.95 | 55 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $9,619.85 | 54 | 2025 |
Source payment records
|
|||||
| XCOPRI Normalized: xcopri |
Drug | SK Life Science, Inc. | $7,679.71 | 15 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $5,513.38 | 12 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $4,834.53 | 14 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $3,855.36 | 17 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $3,500.00 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $451.63 | 40 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $451.63 | 40 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $233.48 | 12 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $232.74 | 12 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $225.12 | 10 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $215.23 | 8 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $167.15 | 5 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $163.03 | 8 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $126.68 | 6 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $104.30 | 8 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $92.64 | 5 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $87.22 | 7 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $85.29 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $75.19 | 4 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $71.98 | 4 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $57.38 | 3 | 2025 |
Source payment records
|
|||||
| NEURACEQ Normalized: neuraceq |
Drug | Life Molecular Imaging Ltd | $54.54 | 2 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $53.60 | 2 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $48.28 | 3 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $33.91 | 2 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $32.28 | 2 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $32.13 | 1 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $24.38 | 1 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $11.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 95 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Briviact briviact |
2025 | Briviact | 2024 | 79 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FYCOMPA fycompa |
2025 | Fycompa | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Nayzilam nayzilam |
2025 | Nayzilam | 2024 | 46 | exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 177 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 293 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 192 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 156 | exact normalized | Medicare Part D |
| VALTOCO valtoco |
2025 | Valtoco | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XCOPRI xcopri |
2025 | Xcopri | 2024 | 67 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
53 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
192 | 40 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
156 | 53 |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
177 | 30 |
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Privigen open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 289 recipient NPIs · example record 1232339064 |
Privigen · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Neurelis, Inc. Exact reporting entity; no affiliate inference |
2025 | VALTOCO open payments reported associated product |
CMS Open Payments — General Payments 16082 supporting records · 5567 recipient NPIs · example record 1219183925 |
Valtoco · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | MAYZENT open payments reported associated product |
CMS Open Payments — General Payments 26 supporting records · 26 recipient NPIs · example record 1200006493 |
Mayzent · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
293 | 72 |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
95 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
79 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Nayzilam open payments reported associated product |
CMS Open Payments — General Payments 9542 supporting records · 3826 recipient NPIs · example record 1224348539 |
Nayzilam · 2024 Exact normalized brand match · 1 Part D row |
46 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 2193 | 403 |
| Pregabalin | Pregabalin | 1069 | 188 |
| Donepezil Hcl | Donepezil Hcl | 1037 | 264 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 912 | 228 |
| Topiramate | Topiramate | 798 | 177 |
| Duloxetine Hcl | Duloxetine Hcl | 786 | 196 |
| Levetiracetam | Levetiracetam | 711 | 139 |
| Primidone | Primidone | 656 | 164 |
| Memantine Hcl | Memantine Hcl | 638 | 155 |
| Amitriptyline Hcl | Amitriptyline Hcl | 594 | 147 |
| Baclofen | Baclofen | 399 | 113 |
| Ropinirole Hcl | Ropinirole Hcl | 365 | 101 |
| Clonazepam | Clonazepam | 350 | 56 |
| Quetiapine Fumarate | Quetiapine Fumarate | 300 | 79 |
| Nurtec Odt | Rimegepant Sulfate | 293 | 72 |
| Lamotrigine | Lamotrigine | 250 | 48 |
| Lacosamide | Lacosamide | 223 | 28 |
| Phenobarbital | Phenobarbital | 220 | 25 |
| Propranolol Hcl Er | Propranolol Hcl | 219 | 55 |
| Oxcarbazepine | Oxcarbazepine | 208 | 42 |
| Sertraline Hcl | Sertraline Hcl | 198 | 41 |
| Qulipta | Atogepant | 192 | 40 |
| Nuplazid | Pimavanserin Tartrate | 177 | 30 |
| Sumatriptan Succinate | Sumatriptan Succinate | 163 | 42 |
| Tizanidine Hcl | Tizanidine Hcl | 162 | 42 |
| Ubrelvy | Ubrogepant | 156 | 53 |
| Propranolol Hcl | Propranolol Hcl | 141 | 37 |
| Diazepam | Diazepam | 140 | 18 |
| Emgality Pen | Galcanezumab-Gnlm | 140 | 32 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 132 | 25 |
| Rizatriptan | Rizatriptan Benzoate | 129 | 37 |
| Aimovig Autoinjector | Erenumab-Aooe | 120 | 28 |
| Divalproex Sodium | Divalproex Sodium | 119 | 25 |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 115 | 25 |
| Amantadine | Amantadine Hcl | 115 | 34 |
| Tramadol Hcl | Tramadol Hcl | 112 | 36 |
| Trazodone Hcl | Trazodone Hcl | 112 | 40 |
| Carbamazepine | Carbamazepine | 109 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 106 | 22 |
| Teriflunomide | Teriflunomide | 104 | 13 |
| Austedo Xr | Deutetrabenazine | 95 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 95 | 17 |
| Aptiom | Eslicarbazepine Acetate | 93 | 13 |
| Dalfampridine Er | Dalfampridine | 92 | 16 |
| Levetiracetam Er | Levetiracetam | 88 | 16 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 87 | 20 |
| Zonisamide | Zonisamide | 86 | 17 |
| Carbamazepine Er | Carbamazepine | 85 | 15 |
| Prednisone | Prednisone | 84 | 19 |
| Rytary | Carbidopa/Levodopa | 81 | 12 |
| Briviact | Brivaracetam | 79 | suppressed |
| Lorazepam | Lorazepam | 79 | 16 |
| Modafinil | Modafinil | 79 | 16 |
| Lamotrigine Er | Lamotrigine | 78 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 75 | 25 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 73 | 11 |
| Topiramate Er | Topiramate | 70 | suppressed |
| Alprazolam | Alprazolam | 69 | 41 |
| Buspirone Hcl | Buspirone Hcl | 68 | 16 |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 67 | suppressed |
| Xcopri | Cenobamate | 67 | suppressed |
| Austedo | Deutetrabenazine | 65 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 15 |
| Methylphenidate Hcl | Methylphenidate Hcl | 63 | suppressed |
| Clobazam | Clobazam | 60 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 60 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | 14 |
| Botox | Onabotulinumtoxina | 53 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 47 | 16 |
| Divalproex Sodium Er | Divalproex Sodium | 46 | 14 |
| Nayzilam | Midazolam | 46 | 22 |
| Ondansetron Odt | Ondansetron | 46 | 12 |
| Lidocaine | Lidocaine | 44 | 14 |
| Naproxen | Naproxen | 44 | 13 |
| Bupropion Xl | Bupropion Hcl | 43 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 43 | 11 |
| Meclizine Hcl | Meclizine Hcl | 42 | suppressed |
| Risperidone | Risperidone | 41 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 13 |
| Entacapone | Entacapone | 38 | suppressed |
| Pramipexole Er | Pramipexole Di-Hcl | 38 | suppressed |
| Carbidopa | Carbidopa | 37 | 11 |
| Meloxicam | Meloxicam | 36 | suppressed |
| Fycompa | Perampanel | 35 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 35 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 33 | suppressed |
| Temazepam | Temazepam | 33 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 32 | suppressed |
| Ingrezza | Valbenazine Tosylate | 31 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Zeposia | Ozanimod Hydrochloride | 30 | suppressed |
| Ajovy Syringe | Fremanezumab-Vfrm | 28 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 28 | 23 |
| Dimethyl Fumarate | Dimethyl Fumarate | 28 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Methocarbamol | Methocarbamol | 28 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 28 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 27 | suppressed |
| Neupro | Rotigotine | 27 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Kesimpta Pen | Ofatumumab | 25 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 25 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 25 | suppressed |
| Rivastigmine | Rivastigmine | 25 | suppressed |
| Mayzent | Siponimod | 24 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 24 | 17 |
| Gocovri | Amantadine Hcl | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Epidiolex | Cannabidiol (Cbd) | 22 | suppressed |
| Fingolimod | Fingolimod Hcl | 22 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 22 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 20 |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 19 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 19 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | suppressed |
| Onfi | Clobazam | 18 | suppressed |
| Topamax | Topiramate | 18 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Oxtellar Xr | Oxcarbazepine | 16 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Lamictal Xr | Lamotrigine | 14 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 14 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 14 | suppressed |
| Trileptal | Oxcarbazepine | 14 | suppressed |
| Betaseron | Interferon Beta-1b | 13 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 13 | suppressed |
| Glatopa | Glatiramer Acetate | 13 | suppressed |
| Rebif Rebidose | Interferon Beta-1a/Albumin | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 12 | suppressed |
| Keppra | Levetiracetam | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Valtoco | Diazepam | 12 | suppressed |
| Vimpat | Lacosamide | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $241,236.20 · 522 records | ARGENX US, INC. | ACTHAR, AMPYRA, AMYVID, AUSTEDO XR, BRIUMVI, Briviact, FYCOMPA, Fintepla, HYQVIA, Hizentra, INBRIJA, INGREZZA, KESIMPTA, KISUNLA, Leqembi, NEURACEQ, NUPLAZID, NURTEC ODT, Nayzilam, PONVORY, QULIPTA, REXULTI, Rystiggo, SKYCLARYS, SPRAVATO, TYSABRI, UBRELVY, ULTOMIRIS, VALTOCO, VUMERITY, VYALEV, VYEPTI, VYVGART, VYVGART HYTRULO, WAINUA, XCOPRI, Xeomin, ZAVZPRET, Zilbrysq | 19 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Austedo Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error